We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The company plans to launch the product in the U.S. market for treatment of “patients suffering from difficult-to-treat calcific peripheral artery disease.” Read More